Drug-resistant tuberculosis: Difference between revisions
From IDWiki
Content deleted Content added
| Line 16: | Line 16: | ||
{| class="wikitable" |
{| class="wikitable" |
||
!Resistance To |
!Resistance To |
||
!Replace With |
|||
!Drug to Stop |
|||
!Drug to Add |
|||
!Regimen |
!Regimen |
||
!Total Duration |
!Total Duration |
||
|- |
|- |
||
|INH |
|||
|INH |
|INH |
||
|FQN |
|FQN |
||
| Line 27: | Line 25: | ||
|6 months from date FQN started |
|6 months from date FQN started |
||
|- |
|- |
||
|INH |
|||
|INH |
|INH |
||
|FQN |
|FQN |
||
| Line 33: | Line 30: | ||
|6 months from date FQN started |
|6 months from date FQN started |
||
|- |
|- |
||
|RMP |
|||
|RMP |
|RMP |
||
|FQN |
|FQN |
||
| Line 39: | Line 35: | ||
|18 months from date FQN started |
|18 months from date FQN started |
||
|- |
|- |
||
|RMP |
|||
|RMP |
|RMP |
||
|None |
|None |
||
| Line 45: | Line 40: | ||
|18 months from date FQN started |
|18 months from date FQN started |
||
|- |
|- |
||
|EMB |
|||
|EMB |
|EMB |
||
|None |
|None |
||
| Line 51: | Line 45: | ||
|6 months from start of therapy |
|6 months from start of therapy |
||
|- |
|- |
||
|PZA |
|||
|PZA |
|PZA |
||
|None |
|None |
||
| Line 57: | Line 50: | ||
|9 months from start of therapy |
|9 months from start of therapy |
||
|- |
|- |
||
|INH+EMB |
|||
|INH+EMB |
|INH+EMB |
||
|FQN |
|FQN |
||
| Line 63: | Line 55: | ||
|6 months from date FQN started |
|6 months from date FQN started |
||
|- |
|- |
||
|INH+PZA |
|||
|INH+PZA |
|INH+PZA |
||
|FQN |
|FQN |
||
| Line 69: | Line 60: | ||
|9 months from date FQN started |
|9 months from date FQN started |
||
|- |
|- |
||
|INH+EMB+PZA |
|||
|INH+EMB+PZA |
|INH+EMB+PZA |
||
|FQN+injectable |
|FQN+injectable |
||
Revision as of 17:58, 18 November 2022
- Mycobacterium tuberculosis infection that is resistant to both first-line drugs, isoniazid and rifampin
Classification
- Multidrug resistant tuberculosis (MDR-TB): resistance to isoniazid and rifampicin
- Extensively drug-resistant tuberculosis (XDR-TB): resistance to at least isoniazid and rifampicin, and to any fluoroquinolone, and to any of the three second-line injectables
- Totally drug-resistant tuberculosis (TDR-TB): not well-defined
Management
- 8 months of an intensive four-drug regimen that includes any four drugs to which it is susceptible, in order of preference:
- Any first-line agents to which it is still susceptible
- A fluoroquinolone (except ciprofloxacin)
- An injectable: kanamycin, or other parenteral agent
- Other second-line agents, starting with ethionamide
- Followed by 12 months of a less intensive regimen (at least three effective drugs), for a total of at least 20 months
| Resistance To | Replace With | Regimen | Total Duration |
|---|---|---|---|
| INH | FQN | 6 months RMP+EMB+PZA+FQN | 6 months from date FQN started |
| INH | FQN | 2 months RMP+EMB+PZA+FQN then 4 months RMP+EMB+FQN | 6 months from date FQN started |
| RMP | FQN | 2 months daily INH+EMB+PZA+FQN then 10-16 months INH+EMB+FQN | 18 months from date FQN started |
| RMP | None | 2 months INH+EMB+PZA, then 16 months INH+EMB | 18 months from date FQN started |
| EMB | None | 2 months INH+RMP+PZA, then 4 months INH+RMP | 6 months from start of therapy |
| PZA | None | 2 months INH+RMP+EMB, then 7 months INH+RMP | 9 months from start of therapy |
| INH+EMB | FQN | 6 months daily RMP+PZA+FQN | 6 months from date FQN started |
| INH+PZA | FQN | 9 months RMP+EMB+FQN | 9 months from date FQN started |
| INH+EMB+PZA | FQN+injectable | 2 months TMP+FQN+injectable, then 7 months RMP+FQN | 9 months from date FQN started |
